Empowering Patients in Clinical Research

At Richmond Pharmacology, we believe that clinical trials should be driven by the needs and experiences of the people who matter most – you, the patients.

That’s why we are fully committed to Patient and Public Involvement (PPI) in everything we do.

Through PPI, we involve patients, caregivers, and the public in reviewing clinical trial materials and providing feedback on trial designs and procedures. Your input ensures that our trials are patient-centred, accessible, and more reflective of real-world needs.

Why PPI Is Important to Us

Icon depicting efficiency

Patient-Focused Design

Your insights help shape how our clinical trials are structured, making sure they are as patient-friendly as possible.

icon depicting waste reduction

Clarity and Accessibility

We want all patient-facing documents, like Participant Information Sheets (PIS) and Informed Consent Forms (ICF), to be clear and easy to follow. Your feedback helps us achieve that.

icon depicting carbon neutrality. plant circling the earth

Collaborative Improvement

Together, we can create a better trial experience for you and future patients.

Get Involved in Our PPI Initiatives

We are inviting you to play an active role in shaping the future of clinical research. Whether you want to participate in focus groups or provide feedback on trial documents, your voice will make a difference.

Help us ensure that clinical trials put patients first. Together, we can make a lasting impact on the future of healthcare.

Join Our Focus Groups – Your Voice Can Make a Difference!

We’re looking for people interested in shaping the future of clinical trials. If you'd like to join our Patient and Public Involvement (PPI) focus groups at Richmond Pharmacology, please complete the form below. We value your insights and experiences to make clinical trials more patient-friendly and accessible.

Please complete all sections to register your interest
Upon submission, your interest will be shared with our team. If selected, we will contact you with further details about upcoming focus groups and next steps.Thank you for your interest in helping us improve clinical trials!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest news

リッチモンド社、Beam Therapeuticsと共にα1アンチトリプシン欠乏症(AATD)の画期的な試験を実施

April 1, 2025
リッチモンドは、Beam Therapeutics が実施中の第1/2相試験において、α1アンチトリプシン欠乏症(AATD)の新たな治療法候補に関する最初の3つの用量レベルの予備的結果が得られたことを発表
Read more

リッチモンド、サステナビリティ・アクセラレータープログラムを通じてESGへの取り組みを強化  

March 31, 2025
私たちは、責任ある持続可能なビジネス成長を促進するために、環境・社会・ガバナンス(ESG)の原則を臨床研究業務に組み込むことに取り組んでいます。
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event